367 related articles for article (PubMed ID: 19822739)
1. Pentamidine reverses the splicing defects associated with myotonic dystrophy.
Warf MB; Nakamori M; Matthys CM; Thornton CA; Berglund JA
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18551-6. PubMed ID: 19822739
[TBL] [Abstract][Full Text] [Related]
2. Chemical reversal of the RNA gain of function in myotonic dystrophy.
Cooper TA
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18433-4. PubMed ID: 19864622
[No Abstract] [Full Text] [Related]
3. A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.
Zhang F; Bodycombe NE; Haskell KM; Sun YL; Wang ET; Morris CA; Jones LH; Wood LD; Pletcher MT
Hum Mol Genet; 2017 Aug; 26(16):3056-3068. PubMed ID: 28535287
[TBL] [Abstract][Full Text] [Related]
4. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy.
Lin X; Miller JW; Mankodi A; Kanadia RN; Yuan Y; Moxley RT; Swanson MS; Thornton CA
Hum Mol Genet; 2006 Jul; 15(13):2087-97. PubMed ID: 16717059
[TBL] [Abstract][Full Text] [Related]
5. In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
González ÀL; Konieczny P; Llamusi B; Delgado-Pinar E; Borrell JI; Teixidó J; García-España E; Pérez-Alonso M; Estrada-Tejedor R; Artero R
PLoS One; 2017; 12(6):e0178931. PubMed ID: 28582438
[TBL] [Abstract][Full Text] [Related]
6. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy.
Ho TH; Savkur RS; Poulos MG; Mancini MA; Swanson MS; Cooper TA
J Cell Sci; 2005 Jul; 118(Pt 13):2923-33. PubMed ID: 15961406
[TBL] [Abstract][Full Text] [Related]
7. Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type I.
Herrendorff R; Faleschini MT; Stiefvater A; Erne B; Wiktorowicz T; Kern F; Hamburger M; Potterat O; Kinter J; Sinnreich M
J Biol Chem; 2016 Aug; 291(33):17165-77. PubMed ID: 27298317
[TBL] [Abstract][Full Text] [Related]
8. Targeting toxic RNAs that cause myotonic dystrophy type 1 (DM1) with a bisamidinium inhibitor.
Wong CH; Nguyen L; Peh J; Luu LM; Sanchez JS; Richardson SL; Tuccinardi T; Tsoi H; Chan WY; Chan HY; Baranger AM; Hergenrother PJ; Zimmerman SC
J Am Chem Soc; 2014 Apr; 136(17):6355-61. PubMed ID: 24702247
[TBL] [Abstract][Full Text] [Related]
9. A novel CUG(exp)·MBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1.
Jahromi AH; Nguyen L; Fu Y; Miller KA; Baranger AM; Zimmerman SC
ACS Chem Biol; 2013 May; 8(5):1037-43. PubMed ID: 23480597
[TBL] [Abstract][Full Text] [Related]
10. Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.
Childs-Disney JL; Stepniak-Konieczna E; Tran T; Yildirim I; Park H; Chen CZ; Hoskins J; Southall N; Marugan JJ; Patnaik S; Zheng W; Austin CP; Schatz GC; Sobczak K; Thornton CA; Disney MD
Nat Commun; 2013; 4():2044. PubMed ID: 23806903
[TBL] [Abstract][Full Text] [Related]
11. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy.
Kanadia RN; Shin J; Yuan Y; Beattie SG; Wheeler TM; Thornton CA; Swanson MS
Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11748-53. PubMed ID: 16864772
[TBL] [Abstract][Full Text] [Related]
12. Pentamidine rescues contractility and rhythmicity in a Drosophila model of myotonic dystrophy heart dysfunction.
Chakraborty M; Selma-Soriano E; Magny E; Couso JP; Pérez-Alonso M; Charlet-Berguerand N; Artero R; Llamusi B
Dis Model Mech; 2015 Dec; 8(12):1569-78. PubMed ID: 26515653
[TBL] [Abstract][Full Text] [Related]
13. A Dimeric 2,9-Diamino-1,10-phenanthroline Derivative Improves Alternative Splicing in Myotonic Dystrophy Type 1 Cell and Mouse Models.
Li J; Nakamori M; Matsumoto J; Murata A; Dohno C; Kiliszek A; Taylor K; Sobczak K; Nakatani K
Chemistry; 2018 Dec; 24(68):18115-18122. PubMed ID: 30302858
[TBL] [Abstract][Full Text] [Related]
14. Reducing levels of toxic RNA with small molecules.
Coonrod LA; Nakamori M; Wang W; Carrell S; Hilton CL; Bodner MJ; Siboni RB; Docter AG; Haley MM; Thornton CA; Berglund JA
ACS Chem Biol; 2013 Nov; 8(11):2528-37. PubMed ID: 24028068
[TBL] [Abstract][Full Text] [Related]
15. New function for the RNA helicase p68/DDX5 as a modifier of MBNL1 activity on expanded CUG repeats.
Laurent FX; Sureau A; Klein AF; Trouslard F; Gasnier E; Furling D; Marie J
Nucleic Acids Res; 2012 Apr; 40(7):3159-71. PubMed ID: 22156369
[TBL] [Abstract][Full Text] [Related]
16. MBNL binds similar RNA structures in the CUG repeats of myotonic dystrophy and its pre-mRNA substrate cardiac troponin T.
Warf MB; Berglund JA
RNA; 2007 Dec; 13(12):2238-51. PubMed ID: 17942744
[TBL] [Abstract][Full Text] [Related]
17. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
[TBL] [Abstract][Full Text] [Related]
18. (CCUG)
Yenigun VB; Sirito M; Amcheslavky A; Czernuszewicz T; Colonques-Bellmunt J; García-Alcover I; Wojciechowska M; Bolduc C; Chen Z; López Castel A; Krahe R; Bergmann A
Dis Model Mech; 2017 Aug; 10(8):993-1003. PubMed ID: 28623239
[TBL] [Abstract][Full Text] [Related]
19. Small molecule kinase inhibitors alleviate different molecular features of myotonic dystrophy type 1.
Wojciechowska M; Taylor K; Sobczak K; Napierala M; Krzyzosiak WJ
RNA Biol; 2014; 11(6):742-54. PubMed ID: 24824895
[TBL] [Abstract][Full Text] [Related]
20. Cytoplasmic CUG RNA foci are insufficient to elicit key DM1 features.
Dansithong W; Wolf CM; Sarkar P; Paul S; Chiang A; Holt I; Morris GE; Branco D; Sherwood MC; Comai L; Berul CI; Reddy S
PLoS One; 2008; 3(12):e3968. PubMed ID: 19092997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
